open access

Vol 26, No 2 (2022)
Original paper
Published online: 2022-04-06
Get Citation

Role of plasma 8-OXO-2’-deoxyguanosine in target organ damage in patients with hypertension and type 2 diabetes

Valeriya Nemtsova1, Anna Shalimova23, Olena Kolesnikova3, Olena Vysotska4, Vira Zlatkina1, Natalia Zhelezniakova2
·
Arterial Hypertension 2022;26(2):78-83.
Affiliations
  1. Educational and Scientific Medical Institute of National Technical University “Kharkiv Polytechnic Institute”, Kharkiv, Ukraine
  2. Kharkiv National Medical University, Kharkiv, Ukraine
  3. Government Institution ‘L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine’, Kharkiv, Ukraine
  4. National Aerospace University H.E. Zhukovsky “Kharkiv Aviation Institute”, Kharkiv, Ukraine

open access

Vol 26, No 2 (2022)
ORIGINAL PAPERS
Published online: 2022-04-06

Abstract

Background: The aim of the study was to determine the prognostic value of 8-oxo-2’-deoxyguanosine (8-OHdG) plasma levels for cardiovascular complications (CVC) development in hypertension (HTN) and type 2 diabetes mellitus (T2DM) comorbidity.

Material and methods: One hundred fifty-six patients (mean age 61.71 ± 0.87 years) with the combined course of HTN stage II and T2DM (group 1) and 100 non-diabetic patients with HTN stage II (mean age 60.59 ± 0.87 years, group 2) were examined. Lipid, carbohydrate metabolism, plasma insulin, plasma 8-OHdG (by ELISA), blood pressure levels were measured. Observation period was 12 months.

Results: Plasma levels of 8-OHdG in the patients’ groups were significantly higher than in the controls (p < 0.001), in the group 1 higher than in group 2 (15.37 ± 0.27 ng/L vs. 14.00 ± 0.29 ng/L, respectively, p = 0.002). Plasma levels of 8-OHdG in group-2 patients who developed cardiovascular complications during observation period were significantly higher than in those without cardiovascular complications (16.47 ± 0.62 ng/L vs. 15.11 ± 0.29 ng/L, respectively, p = 0.046). The ROC analysis made it possible to propose the 8-OHdG plasma level ≥ 15.68 ng/L as an identifier for the cardiovascular complications in patients with studied comorbidity. In group 1, in patients with 8-OHdG plasma level ≥ 15.68 ng/L such cardiovascular risk factors as total cholesterol (TC) (p = 0.034), low density lipoprotein cholesterol (LDL-C) (p = 0.035), systolic blood pressure (p = 0.022), HOMA-IR (p = 0.046) were significantly higher compared with those whose level of this indicator was < 15.68 ng/L.

Conclusion: Determination of the plasma 8-OHdG allows not only for assessment of the severity of oxidative stress, but also for determination of the course and prognosis in comorbidity of HTN and T2DM.

Abstract

Background: The aim of the study was to determine the prognostic value of 8-oxo-2’-deoxyguanosine (8-OHdG) plasma levels for cardiovascular complications (CVC) development in hypertension (HTN) and type 2 diabetes mellitus (T2DM) comorbidity.

Material and methods: One hundred fifty-six patients (mean age 61.71 ± 0.87 years) with the combined course of HTN stage II and T2DM (group 1) and 100 non-diabetic patients with HTN stage II (mean age 60.59 ± 0.87 years, group 2) were examined. Lipid, carbohydrate metabolism, plasma insulin, plasma 8-OHdG (by ELISA), blood pressure levels were measured. Observation period was 12 months.

Results: Plasma levels of 8-OHdG in the patients’ groups were significantly higher than in the controls (p < 0.001), in the group 1 higher than in group 2 (15.37 ± 0.27 ng/L vs. 14.00 ± 0.29 ng/L, respectively, p = 0.002). Plasma levels of 8-OHdG in group-2 patients who developed cardiovascular complications during observation period were significantly higher than in those without cardiovascular complications (16.47 ± 0.62 ng/L vs. 15.11 ± 0.29 ng/L, respectively, p = 0.046). The ROC analysis made it possible to propose the 8-OHdG plasma level ≥ 15.68 ng/L as an identifier for the cardiovascular complications in patients with studied comorbidity. In group 1, in patients with 8-OHdG plasma level ≥ 15.68 ng/L such cardiovascular risk factors as total cholesterol (TC) (p = 0.034), low density lipoprotein cholesterol (LDL-C) (p = 0.035), systolic blood pressure (p = 0.022), HOMA-IR (p = 0.046) were significantly higher compared with those whose level of this indicator was < 15.68 ng/L.

Conclusion: Determination of the plasma 8-OHdG allows not only for assessment of the severity of oxidative stress, but also for determination of the course and prognosis in comorbidity of HTN and T2DM.

Get Citation

Keywords

 arterial hypertension; type 2 diabetes mellitus; plasma 8-oxo-2’-deoxyguanosine; cardiovascular complications

About this article
Title

Role of plasma 8-OXO-2’-deoxyguanosine in target organ damage in patients with hypertension and type 2 diabetes

Journal

Arterial Hypertension

Issue

Vol 26, No 2 (2022)

Article type

Original paper

Pages

78-83

Published online

2022-04-06

Page views

4207

Article views/downloads

586

DOI

10.5603/AH.a2022.0006

Bibliographic record

Arterial Hypertension 2022;26(2):78-83.

Keywords

 arterial hypertension
type 2 diabetes mellitus
plasma 8-oxo-2’-deoxyguanosine
cardiovascular complications

Authors

Valeriya Nemtsova
Anna Shalimova
Olena Kolesnikova
Olena Vysotska
Vira Zlatkina
Natalia Zhelezniakova

References (25)
  1. Forouzanfar MH, Alexander L, Anderson HR, et al. GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(10010): 2287–2323.
  2. Illiash MH, Bazyka OIe, Dovhanych NV, et al. [Hypertension and diabetes mellitus: modern aspects of treatment]. Practitioner. 2016; 5(2): 5–9.
  3. Münzel T, Camici GG, Maack C, et al. Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series. J Am Coll Cardiol. 2017; 70(2): 212–229.
  4. Kalinina EV, Chernov NN, Novichkova MD. Role of glutathione, glutathione transferase, and glutaredoxin in regulation of redox-dependent processes. Biochemistry (Mosc). 2014; 79(13): 1562–1583.
  5. Urbaniak SK, Boguszewska K, Szewczuk M, et al. 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine (8-oxodG) and 8-Hydroxy-2'-Deoxyguanosine (8-OHdG) as a Potential Biomarker for Gestational Diabetes Mellitus (GDM) Development. Molecules. 2020; 25(1).
  6. Marmiy NV, Esipov DS. The biological role of 8-oxo-2'-deoxyguanosine. Moscow University Bulletin Series 16 Biology. 2015; 4: 19–23.
  7. Al-Aubaidy HA, Jelinek HF. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur J Endocrinol. 2011; 164(6): 899–904.
  8. Di Minno A, Turnu L, Porro B, et al. 8-Hydroxy-2-Deoxyguanosine Levels and Cardiovascular Disease: A Systematic Review and Meta-Analysis of the Literature. Antioxid Redox Signal. 2016; 24(10): 548–555.
  9. Kant M, Akış M, Çalan M, et al. Elevated urinary levels of 8-oxo-2'-deoxyguanosine, (5'R)- and (5'S)-8,5'-cyclo-2'-deoxyadenosines, and 8-iso-prostaglandin F as potential biomarkers of oxidative stress in patients with prediabetes. DNA Repair (Amst). 2016; 48: 1–7.
  10. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
  11. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020; 63(2): 221–228.
  12. Unifikovanyi klinichnyi protokol pervynnoi ta vtorynnoi (spetsializovanoi) medychnoi dopomohy: tsukrovyi diabet 2 typu (nakaz MOZ 1118 vid 21.12.2012 r. [In Ukrainian].
  13. Arutyunov A, Dubinina EE, Zyibina NN. [Methods for evaluation of free radical oxidation and antioxidant system of the body: methodical recommendations] . Foliant. 2004: 104c.
  14. Liu A, Wu Q, Guo J, et al. Statins: Adverse reactions, oxidative stress and metabolic interactions. Pharmacol Ther. 2019; 195: 54–84.
  15. Zeng H, Liu Z. Atorvastatin Induces Hepatotoxicity in Diabetic Rats via Oxidative Stress, Inflammation, and Anti-Apoptotic Pathway. Med Sci Monit. 2019; 25: 6165–6173.
  16. Nemtsova VD. The effect of statin therapy on oxidative stress indices in patients with arterial hypertension and type 2 diabetes mellitus. Zaporozhye Med J. 2018; 0(1).
  17. Lorza-Gil E, de Souza JC, García-Arévalo M, et al. Coenzyme Q protects against β-cell toxicity induced by pravastatin treatment of hypercholesterolemia. J Cell Physiol. 2019; 234(7): 11047–11059.
  18. Thomas MC, Woodward M, Li Q, et al. ADVANCE Collaborative Group. Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial. J Am Heart Assoc. 2018; 7(13).
  19. Yıldırım E, İpek E, Bavunoğlu I, et al. The impact of protein oxidation on sustained and white coat hypertension. Anatol J Cardiol. 2017; 17(3): 210–216.
  20. Di Minno A, Turnu L, Porro B, et al. 8-Hydroxy-2-Deoxyguanosine Levels and Cardiovascular Disease: A Systematic Review and Meta-Analysis of the Literature. Antioxid Redox Signal. 2016; 24(10): 548–555.
  21. Al-Aubaidy HA, Jelinek HF. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur J Endocrinol. 2011; 164(6): 899–904.
  22. Urbaniak SK, Boguszewska K, Szewczuk M, et al. 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine (8-oxodG) and 8-Hydroxy-2'-Deoxyguanosine (8-OHdG) as a Potential Biomarker for Gestational Diabetes Mellitus (GDM) Development. Molecules. 2020; 25(1).
  23. Nemtsova V, Bilovol O, Shalimova A. Vascular endothelial growth factor as a marker of endothelial dysfunction in poly- and comorbidity: focus on hypertension, type 2 diabetes mellitus and subclinical hypothyroidism. Arterial Hypertension. 2019; 23(2): 98–104.
  24. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6): 743–753.
  25. Verweij L, Peters RJG, Scholte Op Reimer WJM, et al. Validation of the Systematic COronary Risk Evaluation — Older Persons (SCORE-OP) in the EPIC-Norfolk prospective population study. Int J Cardiol. 2019; 293: 226–230.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl